Académique Documents
Professionnel Documents
Culture Documents
Stable COPD
Global Strategy for Diagnosis, Management and
Prevention of COPD, 2013: Chapters
Manage Comorbidities
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and
Prevention of COPD, 2013: Chapters
Manage Comorbidities
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and Prevention of COPD
Definition of COPD
COPD, a common preventable and treatable
disease, is characterized by persistent airflow
limitation that is usually progressive and
associated with an enhanced chronic
inflammatory response in the airways and the
lung to noxious particles or gases.
Exacerbations and comorbidities contribute to
the overall severity in individual patients.
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and Prevention of COPD
Mechanisms Underlying
Airflow Limitation in COPD
AIRFLOW LIMITATION
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Normal Alveolar Emptying
Alveolar Emptying in COPD
Genes
Infections
Socio-economic
status
Aging Populations
© 2013 Global Initiative for Chronic Obstructive Lung Disease
PATOGENESIS OF COPD
BACTERIAL COLONIZATION
RESPIRATORY EPITHELIAL CELL
(i.e. Increasing of bacterial
DAMAGE
adhesion)
BACTERIAL PRODUCT
(Histamin, protease, etc)
INFLAMATORY RESPONS
DEVELOP TO COPD (granulositosis activation)
INCREASING OF OXIDATIVE
STRESS (antioXidant consumtion)
Global Strategy for Diagnosis, Management and
Prevention of COPD, 2013: Chapters
Manage Comorbidities
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and Prevention of COPD
Diagnosis of COPD
EXPOSURE TO RISK
SYMPTOMS FACTORS
shortness of breath
tobacco
chronic cough occupation
sputum indoor/outdoor pollution
5 FVC
4
Volume, liters
FEV1 = 4L
3
FVC = 5L
2
FEV1/FVC = 0.8
1
1 2 3 4 5 6
Time, sec
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Spirometry: Obstructive Disease
5 Normal
4
Volume, liters
3
FEV1 = 1.8L
2 FVC = 3.2L
Obstructive
FEV1/FVC = 0.56
1
1 2 3 4 5 6
Time, seconds
Assessment of COPD
Assess symptoms
Assess degree of airflow
limitation using spirometry
Assess risk of exacerbations
Assess comorbidities
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and Prevention of COPD
Symptoms of COPD
The characteristic symptoms of COPD are chronic and
progressive dyspnea, cough, and sputum production
that can be variable from day-to-day.
Assessment of COPD
Assess symptoms
Assess degree of airflow limitation using
spirometry
Use the COPD Assessment Test(CAT)
Assess risk of exacerbations
Assess comorbidities or
mMRC Breathlessness scale
or
Clinical COPD Questionnaire (CCQ)
© 2013 Global Initiative for Chronic Obstructive Lung Disease
CAT : COPD Assessment Test
Global Strategy for Diagnosis, Management and Prevention of COPD
Assessment of Symptoms
COPD Assessment Test (CAT): An 8-item
measure of health status impairment in COPD
(http://catestonline.org).
Assessment of Symptoms
Clinical COPD Questionnaire (CCQ): Self-
administered questionnaire developed to
measure clinical control in patients with COPD
(http://www.ccq.nl).
Assessment of COPD
Assess symptoms
Assess degree of airflow limitation
using spirometry
Use spirometry
Assess for grading severity
risk of exacerbations
Assess comorbidities
according to spirometry, using four
grades split at 80%, 50% and 30% of
predicted value
Assessment of COPD
Assess symptoms
Assess degree of airflow limitation
using spirometry
Assess risk of exacerbations
Assess comorbidities
Use history of exacerbations and spirometry.
Two exacerbations or more within the last year
or an FEV1 < 50 % of predicted value are
indicators of high risk
Assess symptoms
Assess degree of airflow limitation using
spirometry
Assess risk of exacerbations
(Exacerbation history)
(C) (D) >2
3 A: Les symptoms, low risk
Risk
Risk
B: More symptoms, low risk
2 1
(A) (B) C: Less symptoms, high risk
1 0
D: More symptoms, high
mMRC 0-1 mMRC > 2 risk
CAT < 10 CAT > 10
Symptoms
(mMRC or CAT score))
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and
Prevention of COPD
Combined Assessment
of COPD
When assessing risk, choose the highest risk
according to GOLD grade or exacerbation
history. One or more hospitalizations for COPD
exacerbations should be considered high risk.)
Differential Diagnosis:
COPD and Asthma
COPD ASTHMA
• Onset in mid-life • Onset early in life (often
childhood)
• Symptoms slowly
progressive • Symptoms vary from day to day
• Long smoking history • Symptoms worse at night/early
morning
• Allergy, rhinitis, and/or eczema
also present
• Family history of asthma
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and Prevention of COPD
Additional Investigations
Chest X-ray: Seldom diagnostic but valuable to exclude
alternative diagnoses and establish presence of significant
comorbidities.
Lung Volumes and Diffusing Capacity: Help to characterize
severity, but not essential to patient management.
Oximetry and Arterial Blood Gases: Pulse oximetry can be
used to evaluate a patient’s oxygen saturation and need for
supplemental oxygen therapy.
Alpha-1 Antitrypsin Deficiency Screening: Perform when COPD
develops in patients of Caucasian descent under 45 years or
with a strong family history of COPD.
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and
Prevention of COPD, 2013: Major Chapters
Manage Comorbidities
© 2013 Global Initiative for Chronic Obstructive Lung Disease
Global Strategy for Diagnosis, Management and Prevention of COPD
Relieve symptoms
Improve exercise tolerance Reduce
symptoms
Improve health status
C D
Carbocysteine
SABA and/or SAMA
GOLD 2 A B
1
Theophylline SABA and/or SAMA
GOLD 1 Theophylline
0